TCG Advisors’s Tvardi Therapeutics TVRD Stock Holding History

TCG Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-42	Closed	-$33K	–	435
2019 Q2	$33K	Hold	42	–	–	0.03%	175
2019 Q1	$30K	Buy	+42	New	+$25.1K	0.03%	185

Other funds holding TVRD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

TCG Advisors's TVRD Position: Q3 2019 in Review

TCG Advisors sold out of Tvardi Therapeutics (TVRD) in Q3 2019, closing a stake of 42 shares — an estimated $33K sold.

TCG Advisors first reported a position in TVRD in Q1 2019 and held it in 2 quarters. The position peaked at $33K in Q2 2019. 144 funds tracked by Wall St. Rank hold TVRD as of Q3 2019.

TCG Advisors reported no remaining Tvardi Therapeutics position as of Q3 2019 after selling out during the quarter.
TCG Advisors sold 42 Tvardi Therapeutics shares in Q3 2019, an estimated $33K.
TCG Advisors first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 2 quarters.
TCG Advisors's Tvardi Therapeutics position peaked at $33K in Q2 2019.
144 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2019.

Based on TCG Advisors's 13F filing for Q3 2019, filed 13 Nov 2019.